UROGEN PHARMA LADENBURG THALMANN HEALTHCARE CONFERENCE JULY 14, 2021 2 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the potential ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Lee Roth - Burns McClellan Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference Call Participants Hannah Adeoye - JPMorgan Chris Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2020 Results Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Sara Sherman - Head, Investor Relations Liz Barrett - President and CEO Dr. Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies Derek Archila - Stifel Hannah Adeoye - J.P. Morgan Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Operator Good morning, ladies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) (State or other jurisd ...

UROGEN PHARMA OPPENHEIMER 31ST ANNUAL HEALTHCARE CONFERENCE MARCH 16, 2021 2 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the pot ...

UROGEN PHARMA J.P. MORGAN 2021 HEALTHCARE CONFERENCE JANUARY 13, 2021 2 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the potentia ...

UroGen Pharma Ltd (NASDAQ:URGN) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Sara Sherman – Head of Investor Relations Liz Barrett – President and Chief Executive Officer Mark Schoenberg – Chief Medical Officer Jeff Bova – Chief Commercial Officer Molly Henderson – Chief Financial Officer Conference Call Participants Ram Selvaraju – H. C. Wainwright Derek Archila – Stifel Leland Gershell – Oppenheimer Eric Joseph – J.P. Morgan Matt Kaplan – Ladenburg Thalmann Operator Go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2020 Earnings Conference Call August 10, 2020 8:30 AM ET Company Participants Kate Bechtold - Senior Director, IR Liz Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - SVP, Commercial Peter Pfreundschuh - CFO Conference Call Participants Boris Peaker - Cowen Leland Gershell - Oppenheimer Paul Choi - Goldman Sachs Matt Kaplan - Ladenburg Thalmann Operator Thank you for standing by and welcome to the UroGen Pharma Second Quarter 2020 Financial Re ...